CARA News and Press, Cara Therapeutics Inc. From 08/09/21

Cara (NASDAQ:CARA) says following a potential FDA approval of Korsuva injection for chronic kidney disease-associated pruritus in hemodialysis later this month, it would launch the drug this half of the year. Korsuva (difelikefalin), which has Priority Review status, has an FDA action date of...

– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., A...

STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...

CARA dropped due to a failed phase 2 trial in its second indication. Lead indication has a PDUFA on Aug 23, and it is unaffected by the other trial's failure. That makes the current drop attractive. For further details see: Cara Therapeutics: PDUFA Ahead Makes Current Dr...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics Third milestone payment related to the development of Oral KORSUVA™ PR Newswire DALLAS , June 11, 2021 /PRNewswire/ -- SWK Holdings Corporation (...

Palm Beach, FL – June 8, 2021 – The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing Cannabidiol markets. The global COVID-19 pandemic outbreak has had an unprec...

Cara Therapeutics (NASDAQ: CARA) is an aspiring biotech company that seeks to combat an extremely common, yet under-the-radar, medical condition -- itchiness. Its efforts hit a stumbling block late last month, however, with the release of not-so-impressive clinical results for...

STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announc...

The following slide deck was published by Cara Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Cara Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation